After COVID-19 brought record-setting investment to the healthcare industry in 2020, this year is shaping up to be even better.…
McAlinden Research PartnersApril 28, 2021
Gene editing trials continue to heat up, as more and more labs initiate testing on humans. Genomics is increasingly popular among…
McAlinden Research PartnersFebruary 4, 2021
A wealth of new data from several leading genomics firms have launched stocks in the sector higher in the fourth…
McAlinden Research PartnersDecember 22, 2020
Drugstore chains already faced secular headwinds heading into 2020, as competition from online sellers, independent prescription delivery services, and retail…
McAlinden Research PartnersOctober 19, 2020
President Trump's bout of COVID-19 launched countless headlines regarding the some of the leading experimental treatments he'd be receiving - therapeutics…
McAlinden Research PartnersOctober 13, 2020
The landscape may be shifting for health insurers, and not for the better. A congressional investigation, rising claims & loss…
McAlinden Research PartnersSeptember 24, 2020
Emerging market healthcare stocks were on fire earlier in the year. While they have taken a breather recently, MRP believes…
McAlinden Research PartnersSeptember 17, 2020
New developments in advanced methods of CRISPR, particularly in base and prime editing, continue to propel the popularity of the…
McAlinden Research PartnersSeptember 1, 2020
COVID-19 has been a gamechanger for telemedicine. A perfect storm scenario saw 5-10 years of progress take place over just…
McAlinden Research PartnersJuly 30, 2020
